OpGen Unveils Next-Generation Molecular Testing, Bioinformatics Program

OpGen has launched its molecular testing and bioinformatics program for gram negative multidrug resistant organism detection and management, the Gaithersburg, Md., devicemaker announced Tuesday.

The launch comprises the company’s Acuitas suite of MDRO products, which are designed to target antibiotic resistance, improve patient outcomes and reduce healthcare costs.

Highlights include the Acuitas Resistome Test’s ability to detect an estimated 50 antibiotic-resistant genes, the Acuitas Whole Genome Sequence Analysis which allows for high-resolution strain typing and sub typing of a full spectrum of resistance genes, and the Acuitas Lighthouse MDRO Management system which offers a detailed MDRO molecular patient profile.

MDROs pose a great risk to public health, a problem heightened by a limited supply of effective antibiotics and dearth of advanced diagnostic tests, says Evan Jones, chairman and CEO. In the U.S., an estimated 23,000 people die from these types of infections.

OpGen was selected to participate in the White House Forum on Antibiotic Stewardship held on Tuesday. The company says its launch helps the administration advance its five-year agenda of developing advanced diagnostics for MDROs though private-public partnerships. — Jason Scott